Bright Minds Biosciences Inc.
DRUG Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$51.09
KIRA · Stoqly’s AI analyst, in plain words
- Bright Minds Biosciences Inc. lost $8.7M in fiscal 2025.
Market cap
$351M
P/E
—
Revenue
—
Net income
−$8.7M
Free cash flow
—
Operating margin
—
Bright Minds Biosciences Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$8.7M
No. It lost money last year.
What Bright Minds Biosciences Inc. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 40-F · Dec 23, 2025
- Legal name
- BRIGHT MINDS BIOSCIENCES INC.
- CIK
- 0001827401
Bright Minds Biosciences Inc. · DRUG
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$6.8M | −$11.7M | −$5.5M | −$2.1M | −$8.7M |
| Diluted EPS | −$3.81 | −$4.74 | −$1.47 | −$0.48 | — |
| Cash | |||||
| Cash from operations | −$5.8M | −$10.6M | −$5.2M | −$1.4M | −$6.2M |
| Share count change | −50.3% | 37.6% | 50.6% | 15.9% | 59.6% |
| Debt and strength | |||||
| Cash and short-term investments | $15.5M | $8.5M | $5.0M | $4.2M | $59.6M |
| Shareholders' equity | $15.2M | $7.7M | $4.9M | $4.1M | $58.9M |
| Current ratio | 31.4x | 8.1x | 24.3x | 11.3x | 36.1x |
| Returns and quality | |||||
| Return on equity | −86.7% | −102.3% | −86.9% | −45.7% | −27.7% |
| Return on tangible equity | −44.9% | −152.8% | −111.3% | −50.3% | −14.8% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$9.8M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bright Minds Biosciences Inc. · DRUG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $51.09 a share, the company is worth $351M.
Source: SEC EDGAR XBRL filings (CIK 0001827401). Data updated October 24, 2026. Filed in CAD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.